H.C. Wainwright analyst Debjit Chattopadhyay called ImmunoGen's agreement with the FDA to expedite the availability of mirvetuximab soravtansine for patients with platinum-resistant ovarian cancer who have experienced disease progression on three prior lines of therapy a "compelling regulatory advance we did not anticipate" and raised his price target on shares to $9 from $5 based on the news. The top-line SORAYA study data are now expected in the first half of 2021, which could lead to a commercial launch mid-2022, which Chattopadhyay said would be about a year ahead of launch estimates. Having an accelerated pathway stems concerns about multiple competitive programs and bolsters confidence in the team, added the analyst, who keeps a Buy rating on ImmunoGen shares.